-
Mashup Score: 2Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions | Esperion Therapeutics, Inc. - 11 month(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023 | Esperion Therapeutics, Inc. - 11 month(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint | Esperion Therapeutics, Inc. - 1 year(s) ago
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Source: Esperion Therapeutics Inc.Categories: Expert Picks, Latest HeadlinesTweet-
CLEAR Outcomes trial meets its primary endpoint, demonstrating statistically significant risk reduction in MACE-4 in patients treated with 180 mg/day #NEXLETOL compared to placebo. https://t.co/eTqYjdB10J
-
Today @EsperionInc shared results from a #CLEAROutcomes primary prevention analysis, as presented by Dr. Nissen at #ADA2023 and published in @JAMA_current. Read more here: https://t.co/Ye4c3zsEeB #ClevelandClinic https://t.co/JrNZacB5iz